# Trastuzumab in a Neo-adjuvant Regimen for HER2+ Breast Cancer - the TRAIN Study

> **NCT00768859** · PHASE2 · COMPLETED · sponsor: **The Netherlands Cancer Institute** · enrollment: 111 (actual)

## Conditions studied

- Breast Cancer
- HER2 Positive

## Interventions

- **DRUG:** paclitaxel, trastuzumab and carboplatin

## Key facts

- **NCT ID:** NCT00768859
- **Lead sponsor:** The Netherlands Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-09
- **Primary completion:** 2011-08
- **Final completion:** 2012-05
- **Target enrollment:** 111 (ACTUAL)
- **Last updated:** 2012-05-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00768859

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00768859, "Trastuzumab in a Neo-adjuvant Regimen for HER2+ Breast Cancer - the TRAIN Study". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT00768859. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*